8-K: Clene Secures $10 Million Debt Facility, Refinances Existing Loan

Clene Inc. has secured a new $10 million debt facility to replace its existing loan with Avenue Capital, improving its cash position and extending its operational runway.

Summary

• Clene Inc. entered into a note purchase agreement on December 17, 2024, to sell senior secured convertible promissory notes totaling $10 million.
• The notes were purchased by Kensington Clene 2024 LLC, 4Life Research, LLC, and La Scala Investments, LLC.
• The notes bear a 12% annual interest rate and mature 18 months after the closing date or upon a change of control.
• Monthly principal repayments of $1 million will begin 13 months after issuance.
• Holders can convert up to 65% of the outstanding principal into common stock at $5.668 per share.
• The proceeds will first be used to repay the existing loan with Avenue Venture Opportunities Fund, L.P., and then for general working capital.
• The company repaid its $7.9 million obligation to Avenue on December 20, 2024, which included principal, interest, a final payment, and an early termination fee.
• The new debt facility is secured by all of Clene's assets.

Sentiment

Score: 6

Explanation: The document is moderately positive as it secures funding and refinances debt, but the high interest rate and potential dilution are concerning.

Positives

• The new debt facility provides Clene with an improved cash position and extended operational runway.
• The conversion feature allows for potential equity upside for the lenders.
• The interest-only period for the first 12 months provides some financial flexibility.
• The company has successfully refinanced its existing debt with Avenue Capital.
• The new debt facility will allow Clene to generate additional data to support the new drug application of CNM-Au8 for ALS.

Negatives

• The debt carries a 12% annual interest rate, which is a significant cost of capital.
• The debt is secured by all of Clene's assets, increasing the risk for the company.
• The company is obligated to make monthly principal repayments of $1 million starting 13 months after issuance.
• The company is reliant on debt financing to fund its operations.

Risks

• The company's ability to meet its debt obligations is dependent on its future financial performance.
• The conversion of debt to equity could dilute existing shareholders.
• The company's ability to obtain regulatory approval for CNM-Au8 is not guaranteed.
• The company is reliant on a small number of related parties for financing.
• The company is subject to covenants under the loan agreement, including a requirement to maintain a minimum cash balance of $2 million.

Future Outlook

Clene intends to use the proceeds from the new debt facility to generate additional data to support the new drug application of CNM-Au8 for ALS via an accelerated regulatory pathway.

Management Comments

• Rob Etherington, President and CEO of Clene, stated that the proceeds from the new debt facility will allow Clene the cash runway to generate the additional data the U.S. Food and Drug Administration has requested from our expanded access programs.
• Rob Etherington also expressed gratitude for the support of long-standing investors.

Industry Context

This announcement is relevant to the biopharmaceutical industry, particularly companies focused on developing treatments for neurodegenerative diseases. The financing will allow Clene to continue its clinical development program for CNM-Au8.

Comparison to Industry Standards

• The 12% interest rate on the debt is relatively high, suggesting that Clene may have limited access to lower-cost financing options.
• The conversion feature at a 130% premium to the stock price is a positive for the lenders, but it could be dilutive to existing shareholders if the stock price does not increase significantly.
• The use of related parties for financing is not uncommon in the biotech industry, but it can raise concerns about potential conflicts of interest.
• The company's focus on an accelerated regulatory pathway for CNM-Au8 is consistent with the industry trend of seeking faster approvals for promising therapies.

Related Party Transactions

• The purchasers of the notes, Kensington Clene 2024 LLC, 4Life Research, LLC, and La Scala Investments, LLC, have pre-existing relationships with the Company.
• Kensington is controlled and managed by Alison Mosca, a member of the board of directors of the Company.
• 4Life has exclusive license and supply agreements with the Company, and its co-founder and chairman, David Lisonbee, is a member of the board of directors of Clene Nanomedicine, Inc., a wholly-owned subsidiary of the Company.
• La Scala is also controlled by Mr. Lisonbee.

Stakeholder Impact

• Shareholders may experience dilution if the convertible notes are converted into common stock.
• Employees may benefit from the improved financial stability of the company.
• Customers may benefit from the continued development of CNM-Au8.
• Creditors may be impacted by the new debt facility.
• Suppliers may benefit from the company's improved cash position.

Next Steps

• Clene will use the proceeds from the debt facility to repay the Avenue loan and for general working capital.
• The company will generate additional data to support the new drug application of CNM-Au8 for ALS.
• Clene will enter into a registration rights agreement with the purchasers of the notes.
• The company will file a registration statement covering the resale of any conversion shares.

Key Dates

Keywords

debt financing, convertible notes, senior secured, refinancing, CNM-Au8, ALS, neurodegenerative diseases, biopharmaceutical, working capital, Avenue Capital, Kensington Clene, 4Life Research, La Scala Investments